论文部分内容阅读
目的:探讨环氧化酶-2(COX-2)在上皮性卵巢肿瘤的表达及环氧化酶-2抑制剂塞来昔布(celecoxib)在体外对人卵巢癌A2780细胞株增殖的影响。方法:①采用免疫组化SP法检测COX-2在65例上皮性卵巢癌、18例交界性与18例良性上皮性卵巢肿瘤及9例正常卵巢组织中的表达;②采用四甲基偶氮唑蓝(MTT)法观察塞来昔布在体外对A2780细胞增殖的影响;③流式细胞仪(FCM)测定塞来昔布在体外对A2780细胞周期的影响。结果:①COX-2在上皮性卵巢癌组(73.80%)及交界性卵巢肿瘤组的表达(66.70%)显著高于良性卵巢肿瘤组(16.70%)及正常卵巢组(11.10%),均P<0.05;②MTT显示,塞来昔布在体外以时间-剂量依赖方式抑制A2780增殖(P<0.05);③塞来昔布作用72 h后A2780细胞周期呈剂量依赖方式出现G0/G1期阻滞(P<0.05)。结论:①COX-2在交界性及恶性上皮性卵巢肿瘤中的表达明显增强,COX-2可能在交界性及恶性上皮性卵巢肿瘤的发生、发展中起一定作用;②体外特异性COX-2抑制剂(塞来昔布)能够抑制卵巢癌A2780细胞株增殖,有可能成为卵巢癌化疗的有效药物。
Objective: To investigate the expression of cyclooxygenase-2 (COX-2) in epithelial ovarian tumors and the effect of cyclooxygenase-2 inhibitor celecoxib on the proliferation of human ovarian cancer A2780 cell line in vitro. Methods ① Immunohistochemical SP method was used to detect the expression of COX-2 in 65 cases of epithelial ovarian cancer, 18 cases of borderline and 18 cases of benign epithelial ovarian tumors and 9 cases of normal ovarian tissue. The effect of celecoxib on the proliferation of A2780 cells was observed by MTT assay; ③ The effect of celecoxib on the cell cycle of A2780 cells was analyzed by flow cytometry (FCM). Results ① The expression of COX-2 in epithelial ovarian cancer (73.80%) and borderline ovarian tumor (66.70%) was significantly higher than that in benign ovarian tumor (16.70%) and normal ovary (11.10%), both P < 0.05). (2) MTT showed that celecoxib inhibited A2780 proliferation in a time-and-dose-dependent manner in vitro (P <0.05); ③ G0 / G1 phase arrest occurred in A2780 cell cycle in a dose- P <0.05). Conclusions: ①The expression of COX-2 in borderline and malignant epithelial ovarian tumors was significantly increased, COX-2 may play a role in the occurrence and development of borderline and malignant epithelial ovarian tumors; ② In vitro specific COX-2 inhibition The agent (celecoxib) can inhibit the proliferation of ovarian cancer cell line A2780 and may become an effective drug for ovarian cancer chemotherapy.